Genetic and biochemical factors associated with variation in blood pressure in a genetic isolate

Hypertension

Volumn 27, Issue 2, 1996, Pages 308-312

  Hegele, Robert A ^a   Brunt, J Howard ^b   Connelly, Philip W ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

Author keywords

genetics, biochemical; hypertension, genetic; lipid metabolism

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSINOGEN; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLESTERASE; BLOOD CLOTTING FACTOR 7; DIPEPTIDYL CARBOXYPEPTIDASE; LIPOPROTEIN LIPASE; LIPOPROTEIN RECEPTOR; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; RECEPTOR PROTEIN; RENIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING; CANADA; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ETHNIC GROUP; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 0030027930     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.2.308     Document Type: Article

References (32)

1. Ward RH. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology. Diagnosis and Management. New York, NY: Raven Press; 1990:81-100.
2. Williams RR, Hunt SC, Hopkins PN, Hasstedt SJ, Wu LL, Lalouel JM. Finding the genes for human hypertension. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis X. Amsterdam, Netherlands: Elsevier Science BV; 1994:856-861.
3. Fuh MMT, Shieh SM, Wu DA, Chen YDI, Reaven GM. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med. 1987;147:1035-1038.
4. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannell WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA. 1986;256:2835-2838.
5. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
6. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the angiotensinogen gene is associated with variation in blood pressure in a genetic isolate. Circulation. 1994;90:2207-2212.
7. Hegele RA, Evans AJ, Tu L, Ip G, Brunt JH, Connelly PW. A genegender interaction affecting lipoproteins in a genetic isolate, Arterioscler Thromb. 1994;14:671-678.
8. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated wild variation in blood pressure in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15:89-95.
9. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15:861-871.
10. Brunt JH, Love EJ. Hypertension and its correlates in the Hutterite community of Alberta. Can J Public Health. 1992;83:362-364.
11. Connelly PW, MacLean DR, Horlick L, O'Connor B, Petrasovits A,: Little JA. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Can Med Assoc J. 1992;146:1977-1987.
12. MacLean DR, Petrasovits A, Nargundkar M, Connelly PW, MacLeod E, Edwards A, Hessel P. Canadian heart health surveys: a profile of cardiovascular risk: survey methods and data analysis. Can Med Assoc J. 1992;146:1971-1976.
13. SAS Institute Inc. SAS/STAT Guide for Personal Computers. Version 6 ed. Cary, NC: SAS Institute Inc; 1987.
14. Chan L, Boerwinkle E. Structure, function, molecular genetics and epidemiology of apolipoprotein B. Semin Liver Dis. 1992;12:311-320.
15. Humphries SE. Life style, genetic factors and the risk of heart attack: the apolipoprotein B gene as an example. Biochem Soc Trans. 1993;21:569-582.
16. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
17. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 1990;86:75-79.
18. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
19. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
20. Miller BC, Hultin MB, Jesty J. Altered factor VII activity in hemophilia. Blood. 1985;65:845-849.
21. Meade TW, Chakrabatri R, Haines AP, North WRS, Stirling Y, Thompson SG. Haemostatic factors and cardiovascular death: the results of an early prospective study. Lancet. 1980;1:1050-1054.
22. Moor E, Silveira A, van't Hooft F, Suontaka AM, Eriksson P, Blomback M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age: role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol. 1995;15:655-664.
23. Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels are determined by factor VII genotype and plasma triglyceride concentrations. Arterioscler Thromb. 1994;14:193-198.
24. Ferraninni E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance to essential hypertension. N Engl J Med. 1987;317:350-357.
25. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealy JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
26. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1988(suppl I):II-127-II-134.
27. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK. Non-modulation as an intermediate phenotype for hypertension. Hypertension. 1992;20:788-796.
28. van Hooft IMS, Grobbee DE, Frolich M, Pols HAP, Hofman A. Alterations in calcium metabolism in young people at risk for primary hypertension: the Dutch Hypertension and Offspring Study. Hypertension. 1993;21:267-272.
29. Hunt SC, Wu LL, Hopkins PN, Stults BM, Kuida H, Ramirez ME, Lalouel JM, Williams RR. Apolipoprotein, low density lipoprotein subtraction and insulin associations with familial combined hyperlipidemia: study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis. 1989;9:335-344.
30. Raccah D, Pettenuzzo-Nollo A, Provendier O, Boucher L, Cozic JA, Gorlier R, Hulin P, Sicard J, Vague P. Comparison of the effects of captopril and nicardipine on insulin sensitivity and thrombolic profile in subjects with hypertension and android obesity. Am J Hypertens. 1994;7:731-738.
31. Lander ES. Finding similarities and differences among genomes. Nat Genet. 1993;4:5-6.
32. Goo SW, Thompson EA. A Monte Carlo method for combined segregation and linkage analysis. Am J Hum Genet. 1992;51:1111-1126.